Salivary CD44, Total Protein ID Recurrence Risk in Head and Neck Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- Elevated salivary levels of CD44 and total protein (TP) can identify head and neck cancer patients with an increased risk for cancer recurrence, according to a study published online Aug. 15 in JAMA Otolaryngology-Head and Neck Surgery.
Elizabeth J. Franzmann, M.D., from the University of Miami Health System and Jackson Memorial Hospital, and colleagues conducted a multi-institutional nonrandomized clinical trial testing a novel diagnostic/screening assay to examine whether soluble CD44 and TP are useful for monitoring head and neck cancer recurrence in a point-of-care (POC) test. Oral rinses were collected at pretreatment baseline and at three, six, 12, and 18 months after completion of therapy. To define disease status, participants were followed for three years.
Among the 172 patients who were enrolled, the researchers found an association for tumor site with test results at baseline; a higher baseline positive POC test rate was seen for patients with oral cavity cancer versus oropharyngeal cancer (92.2 versus 77.3 percent). A higher CD44 level showed a significant association with a higher risk for recurrence using Cox regression models with CD44 or TP level as a time-varying covariate (hazard ratio, 1.06). Higher CD44 and TP levels were associated with increased hazard ratios of recurrence of 1.13 and 3.51, respectively, in a multivariate adjusted analysis.
“Our study suggests biomarker detection in saliva collected from an oral rinse after initial treatment offers potential to readily assess recurrence risk,” Franzmann said in a statement. “Elevated levels of either of two biomarkers were associated with disease return.”
One author disclosed ties to the biopharmaceutical industry and is inventor of the intellectual property used in the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Low Alcohol Use Disorder Treatment Rates Seen in Cancer Survivors
THURSDAY, May 29, 2025 -- For U.S. adult cancer survivors with a new alcohol use disorder (AUD) diagnosis, the one-year cumulative incidence of AUD treatment initiation was 14.3...
Total Number of Excess Deaths >14.7 Million in U.S. in 1980 to 2023
THURSDAY, May 29, 2025 -- There were 14,735,913 excess deaths in the United States during 1980 to 2023 compared with other high-income countries (HICs), according to a research...
Earlier Natural Menopause Risk Increased for Women in Socially Vulnerable Neighborhoods
THURSDAY, May 29, 2025 -- Women residing in U.S. neighborhoods with high social vulnerability have a higher risk for earlier natural menopause, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.